An NSF International Company Strategy for Drug-Device Combinations - Navigate the regulatory labyrinth
Monday the 9th September 2013
By John Worroll, NSF-DBA
Drug-device combinations have always been a challenge to the regulatory approval process. The main problem for the manufacturer can be determining on which side of the drug/device borderline the product falls and hence whether it will be regulated as a medicine or as medical device.
See more at: www.contractpharma.com
